Survival outcomes are relatively high for children with ALL but genetics, insufficient chemotherapy treatment, and the risk of relapse may factor into the reduced survival outcomes in adult patients.
A review of case studies that outline treatment decisions based on patient and disease characteristics.
As the life expectancy for patients with beta thalassemia continues to increase, more and more patients are experiencing age-related complications.
Treatment regimens including immunomodulatory agents or proteasome inhibitors could lead to development of peripheral neuropathy.
Researchers reviewed the diagnosis and management of several pregnancy-specific causes of thrombocytopenia.
CAR-T therapy can sometimes lead to immune system dysfunction, subsequent hypogammaglobulinemia, and the need for antibody replacement therapy.
Antiplatelet therapy is used to manage cardiovascular events but can lead to increased risk for bleeding events both mild and severe.
Renal complications occur in more than half of patients with beta thalassemia, but research on their epidemiology and treatment is limited.
Due to conflicting literature, there is currently no consensus on the appropriate standard of care for managing polycythemia vera.